The state of dietary supplement adverse event reporting in the United States

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 10, 2008, Pages 962-970

  Gardiner, Paula ^a,b   Sarma, Dandapantula N ^a   Dog, Tieraona Low ^a   Barrett, Marilyn L ^a   Chavez, Mary L ^a   Ko, Richard ^a   Mahady, Gail B ^a   Marles, Robin J ^a   Pellicore, Linda S ^a   Giancaspro, Gabriel I ^a  

^a UNITED STATES PHARMACOPEIA   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse event reporting; Dietary supplements

Indexed keywords

AMINO ACID DERIVATIVE; ARISTOLOCHIC ACID; HERBACEOUS AGENT; KAVA; MINERAL; NATURAL PRODUCTS AND THEIR SYNTHETIC DERIVATIVES; PLANT EXTRACT; VITAMIN;

ABDOMINAL DISCOMFORT; ANAPHYLAXIS; CEREBROVASCULAR ACCIDENT; DIARRHEA; DIET SUPPLEMENTATION; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INFORMATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EDUCATION PROGRAM; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GOOD MANUFACTURING PRACTICE; HEALTH CARE PERSONNEL; HEALTH EDUCATION; HUMAN; INCIDENCE; KIDNEY FAILURE; MEDICAL INFORMATION; MEDICATION ERROR; MEDLINE; NAUSEA; PHARMACOEPIDEMIOLOGY; POISON CENTER; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SEIZURE; TOXIC HEPATITIS; UNITED STATES; URTICARIA;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DIETARY SUPPLEMENTS; HUMANS; POISON CONTROL CENTERS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 57749113289     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1627     Document Type: Review

References (58)

1. Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Adv Data 2004; 343: 1-19.
2. Millen AE, Dodd KW, Subar AF. Use of vitamin, mineral, nonvitamin, and nonmineral supplements in the United States: the 1987, 1992, and 2000 National Health Interview Survey results. J Am Diet Assoc 2004; 104(6): 942-950.
3. Anonymous. Dietary Supplement Health and Education Act 1994. Center for Food Safety and Applied Nutrition: Washington, DC, 1994. http://www.fda.gov/opacom/laws/dshea.html#sec3
4. Gardiner P, Graham RE, Legedza AT, Eisenberg DM, Phillips RS. Factors associated with dietary supplement use among prescription medication users. Arch Intern Med 2006; 166(18): 1968-1974.
5. Radimer K, Bindewald B, Hughes J, Ervin B, Swanson C, Picciano MF. Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000. Am J Epidemiol 2004; 160(4): 339-349.
6. Ni H, Simile C, Hardy AM. Utilization of complementary and alternative medicine by United States adults: results from the 1999 national health interview survey. Med Care 2002; 40(4): 353-358.
7. Gardiner P, Graham R, Legedza AT, Ahn AC, Eisenberg DM, Phillips RS. Factors associated with herbal therapy use by adults in the United States. Altern Ther Health Med 2007; 13(2): 22-29.
8. Anonymous. NBJ's Raw Material & Ingredient Supply Report 2006, pages 1-14, Nutrition Business Journal, New Hope Natural Media, San Diego, CA 92116, USA.
9. Betz J. Botanicals and other supplements. JAOACI 2001; 84: 214-218.
10. Bhattacharyya L, Cecil T, Dabbah R, et al. The value of USP public standards for therapeutic products. Pharm Res 2004; 21(10): 1725-1731.
11. Atwater J, Montgomery J, Roll D. The USP dietary supplement verification program: helping pharmacists and consumers select dietary supplements. U.S. Pharmacist 2005; 30: 61-64.
12. Anonymous. New admission criteria for dietary supplements. Pharmacopeial Forum 2003; 29(1): 19-20.
13. Anonymous. Office of Inspector General Report: adverse event reporting for dietary supplements: an inadequate safety valve. Washington, DC, 2001.
14. Anonymous. Dietary Supplements: A Framework for Evaluating Safety. Institute of Medicine & National Research Council; The National Academies Press: Washington, DC, 2005.
15. Hawkins B. NIH conference on dietary supplements. American Society of Health-System Pharmacists. Thromb Res 2005. Epub ahead of print.
16. Kelly WN, Arellano FM, Barnes J, et al. Guidelines for submitting adverse event reports for publication. Pharmacoepidemiol Drug Saf 2007; 16(5): 581-587.
17. Kroll DJ. ASHP statement on the use of dietary supplements. Am J Health Syst Pharm 2004; 61(16): 1707-1711.
18. Morrow JD, Edeki TI, El Mouelhi M, et al. American Society for Clinical Pharmacology and Therapeutics position statement on dietary supplement safety and regulation. Clin Pharmacol Ther 2005; 77(3): 113-122.
19. WHO. Guidelines on Safety Monitoring of Herbal Medicines in Pharmacovigilance systems. WHO Department of Essential Drugs and Medicines Policy: Geneva, 2004.
20. Suchard JR, Suchard MA, Steinfeldt JL. Physician knowledge of herbal toxicities and adverse herb-drug interactions. Eur J Emerg Med 2004; 11(4): 193-197.
21. Berman BM, Singh BK, Lao L, Singh BB, Ferentz KS, Hartnoll SM. Physicians' attitudes toward complementary or alternative medicine: a regional survey. J Am Board Fam Pract 1995; 8(5): 361-366.
22. Coppens P, da Silva MF, Pettman S. European regulations on nutraceuticals, dietary supplements and functional foods: a framework based on safety. Toxicology 2006; 221(1): 59-74.
23. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30(2): 239-245.
24. Busto U, Naranjo CA, Sellers EM. Comparison of two recently published algorithms for assessing the probability of adverse drug reactions. Br J Clin Pharmacol 1982; 13(2): 223-227.
25. Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AR. An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use. JAMA 1979; 242(7): 623-632.
26. Shekelle PG, Hardy ML, Morton SC, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA 2003; 289(12): 1537-1545.
27. Kelly WN, Arellano FM, Barnes J, et al. Guidelines for submitting adverse event reports for publication. Drug Saf 2007; 30(5): 367-373.
28. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey [see comment]. JAMA 1998; 280(18): 1569-1575.
29. Kemper KJ, O'Connor KG. Pediatricians' recommendations for complementary and alternative medical (CAM) therapies. Ambul Pediatr 2004; 4(6): 482-487.
30. Corbin Winslow L, Shapiro H. Physicians want education about complementary and alternative medicine to enhance communication with their patients. Arch Intern Med 2002; 162(10): 1176-1181.
31. Hudson K, Brady E, Rapp D. What you and your patients should know about herbal medicines. JAAPA 2001; 14(11): 27-29. 32-34.
32. Glintborg B, Andersen SE, Spang-Hanssen E, Dalhoff K. The use of over-the-counter drugs among surgical and medical patients. Eur J Clin Pharmacol 2004; 60(6): 431-437.
33. Silverstein DD, Spiegel AD. Are physicians aware of the risks of alternative medicine? J Community Health 2001; 26(3): 159-174.
34. Kwan D, Hirschkorn K, Boon H. U.S. and Canadian pharmacists' attitudes, knowledge, and professional practice behaviors toward dietary supplements: a systematic review. BMC Complement Altern Med 2006; 6: 31.
35. Anonymous. Dietary Supplement Adverse Event Reporting. Form MedWatch 3500, 2008. http://www.cfsan.fda.gov/~dms/ds-rept.html
36. Anonymous. USP-ISMP Medication Error Reporting Program (MERP), 2008. https://www.ismp.org/orderforms/reporterrortoISMP.asp
37. Dennehy CE, Tsourounis C, Horn AJ. Dietary supplement-related adverse events reported to the California Poison Control System. Am J Health Syst Pharm 2005; 62(14): 1476-1482.
38. Palmer ME, Haller C, McKinney PE, et al. Adverse events associated with dietary supplements: an observational study. Lancet 2003; 361(9352): 101-106.
39. Litovitz TL, Klein-Schwartz W, White S, et al. 1999 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2000; 18(5): 517-574.
40. Litovitz TL, Klein-Schwartz W, Rodgers GC, Jr, et al. 2001 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2002; 20(5): 391-452.
41. Woolf AD, Watson WA, Smolinske S, Litovitz T. The severity of toxic reactions to ephedra: comparisons to other botanical products and national trends from 1993-2002. Clin Toxicol (Phila) 2005; 43(5): 347-355.
42. Lai MW, Klein-Schwartz W, Rodgers GC, et al. 2005 Annual Report of the American Association of Poison Control Centers' national poisoning and exposure database. Clin Toxicol (Phila) 2006; 44(6-7): 803-932.
43. Anonymous. Regulation of Dietary Supplements: A Review of Consumer Safeguards. Washington, DC, 2005, http://www.fda.gov/ola/2006/ dietsupp0309.html
44. Anonymous. Dietary Supplement and Nonprescription Drug Consumer Protection Act of 2006. Center for Food Safety and Applied Nutrition, 2006. http://www.fda.gov/Cder/regulatory/public_law_109462.pdf
45. Nortier JL, Martinez MC, Schmeiser HH, et al. Urothelial carcinoma associated with the use of a Chinese herb ( Aristolochia fangchi). N Engl J Med 2000; 342(23): 1686-1692.
46. Stillman AE, Huxtable RJ, Fox D, Hart M, Bergeson P. Pyrrolizidine (Senecio) poisoning in Arizona: severe liver damage due to herbal teas. Ariz Med 1977; 34(8): 545-546.
47. Stillman AS, Huxtable R, Consroe P, Kohnen P, Smith S. Hepatic veno-occlusive disease due to pyrrolizidine (Senecio) poisoning in Arizona. Gastroenterology 1977; 73(2): 349-352.
48. Wu KM, Farrelly JG, Upton R, Chen J. Complexities of the herbal nomenclature system in traditional Chinese medicine (TCM): lessons learned from the misuse of Aristolochia-related species and the importance of the pharmaceutical name during botanical drug product development. Phytomedicine 2007; 14(4): 273-279.
49. De Smet P, D'Arcy P. Drug interactions with herbal and other non-orthodox remedies. In Drug Interactions, Wellington P, D'Arcy P (eds). Springer Verlag: Heidelberg, 1996: 327-352.
50. FDA. Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements; Final Rule. FDA: Washington, DC, 2007.
51. Anonymous. Manufacturing Practices for Dietary Supplements <2750>, Vol. 1. US Pharmacopeia (USP30-NF25): Rockville, MD, 2007.
52. Lynch E, Braithwaite R. A review of the clinical and toxicological aspects of 'traditional' (herbal) medicines adulterated with heavy metals. Expert Opin Drug Saf 2005; 4(4): 769-778.
53. Cheung TP, Xue C, Leung K, Chan K, Li CG. Aristolochic acids detected in some raw Chinese medicinal herbs and manufactured herbal products - a consequence of inappropriate nomenclature and imprecise labelling? Clin Toxicol (Phila) 2006; 44(4): 371-378.
54. Koh HL, Woo SO. Chinese proprietary medicine in Singapore: regulatory control of toxic heavy metals and undeclared drugs. Drug Saf 2000; 23(5): 351-362.
55. Ernst E. Toxic heavy metals and undeclared drugs in Asian herbal medicines. Trends Pharmacol Sci 2002; 23(3): 136-139.
56. Saper RB, Kales SN, Paquin J, et al. Heavy metal content of ayurvedic herbal medicine products. JAMA 2004; 292(23): 2868.
57. Mozzicato P. Standardised MedDRA queries: their role in signal detection. Drug Saf 2007; 30(7): 617-6179.
58. Anonymous. Herbal ATC classification, 2007. http://www.who-umc.org/ DynPage.aspx?id=13136&mn=1512#7